By Michael Dabaie
Turning Point Brands Inc. said the U.S. Food and Drug Administration denied the company's application to market some of its vapor products.
Turning Point said it will continue to engage with the FDA and other stakeholders as it considers options, including a formal appeal of the decision and potential legal relief.
"While we believe the FDA's current conclusion is misguided, we will continue our dialogue with the agency in search of a path forward," said Chief Executive Larry Wexler.
Turning Point's premarket tobacco product application included an in-depth toxicological review, a clinical study, and studies on patterns and likelihood of use, the company said.
Write to Michael Dabaie at email@example.com
(END) Dow Jones Newswires